Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Fantastic week for PRED in terms of announcements regarding growing the business.
Lousy week psychologically with the stock price.
Sounds like most of us weren't all that surprised the PPS didn't move much, even with the great PRs. That doesn't mean we weren't disappointed.
That should tell people something. PRED management wasn't surprised by the lack of price movement either. They knew exactly how this week was going to play out.
In addition, Thomas states the gameplan is still to move forward with the uplist to NASDAQ, rather than consider alternative paths. In fact, he labeled alternative paths "silly". That's a pretty strong statement.
Conclusion: Management is still focusing on growing the business, setting the stage, and getting ready to make their move. We don't have to like the wait, but we chose to invest in this company with these managers. Have some faith they know what they are doing, and have developed a strategy that will be effective.
Prediction: We will get the NASDAQ uplist before the end of 2019. I also predict enough information will be released before the uplist, and the stock price will far exceed any minimum price required to qualify for NASDAQ.
As great as the announcements were this past week, we haven't seen anything yet. And that's saying something since we had all been anticipating the ARTguide launch PR for quite some time now, and hoping the impact would have been felt immediately.
The PRED sledgehammer is coming.
Tick....tock....shorts....
PRED STRONG.
Hey Thomas - How concerned is PRED management with uplisting to NASDAQ?
When it finally happens, can we all party in Vegas together, and burn the city to the ground?!
"Awesome news today. And the stock is up a lousy penny. This company is very far off the radar. Nasdaq will cure that. how about a conditional approval?" - Stockboy
I agree, 100%, with Stockboy. I too have been stating PRED is well below the radar.
In a 3 day period, we get news of...
1) a change to one of the top accounting firms, Deloitte
2) joining forces with the top notch PR firm, Antennae
3) the official launch of ARTguide test during upcoming Reproductive conference 10/12-16.
This is a grand slam week on these 3 pieces of news, and basically our stock price doesn't change?! This is beyond absurd, although I'm not surprised at this point.
I also agree PRED will not give up on NASDAQ and pursue an alternate path forward like OTCQX, unless there is no other option.
Thomas reminded us PRED spent A LOT of money over the past few years prepping for the NASDAQ, and they're not going to just give it up (even temporarily) without a serious fight. I think this fight is beyond just business now, and has become personal to PRED. Our managers didn't get to the apex of their careers by getting pushed around, and tucking tail and running from a challenge.
There are a lot of ways PRED can get their pps up for a certain time frame, so it's pointless speculating on all of their options.
I wonder how many institutional investors are aware of PRED, and are just itching to take a bite out of the float.
I wonder what is going to happen to our stock price when PRED determines it's time to no longer be below the radar. To those of you who keep asking if some of us really believe PRED is staying below the radar, the answer is 'obviously'. Trust me, you'll know, and won't have to ask that question anymore, when we're above the radar.
I am so thankful I am not a short on this stock. Us longs have taken it in the teeth for a pretty good stretch here. I'm ready for PRED management to start throwing their own blows. They've done a fantastic job growing the business, laying the groundwork with PRs, and joining forces with the right companies.
I cannot wait to watch management really start taking the fight to the enemy.
PRED STRONG
Like I keep saying, there is a treasure trove of information within posts from Thomas. This one is from back in August, but now we have more context regarding some of what he wrote.
Thomas: "Why would other therapeutic technologies come to PRED? Simple because their law firm is WSGR, the world's leading life science law firm which I have posted comments about on this blog. WSGR is also one of the greatest match-markers in the history of any law firm."
Translation - Because PRED has such a world class law firm in WSGR, other companies like Thermo Fisher and Deloitte will be much more likely to be willing to pause and take a real look at what PRED brings to the table, and consider partnerships. Connecting the dots, it's safe to assume WSGR played a major role in connecting PRED with both TMO and Deloitte. It pays to have big dogs as friends, and gives us credibility.
I have no doubt having WSGR also helped PRED land the all-star management and Directors they pulled from major roles in other successful companies.
And now that Thermo Fisher and Deloitte have vetted PRED and its managers, and signed on, other big companies will be that much more likely to have faith this OTC company is going serious places.
Putting the pieces together…..
Timeline:
After the hit piece, PRED announces rather than wasting time with rebuttals, and a potentially endless back and forth banter with shady individuals espousing what would soon prove to be misinformation across the board, management is choosing to remain laser focused on growing their business.
Plenty of longs voice their displeasure with management’s strategy.
Flashback to August 15th, 2019 when Thomas posted the photos of PRED’s CEO, Bradley Robinson, being shown where PRED would ring the bell at NASDAQ.
Most of us thought the NASDAQ uplist was imminent at that point, myself included. In reality, it was going to take a little longer, but let’s take a look at some important information.
Shortly after the photos were released, we hear from Thomas that PRED’s management, including Mr Robinson, is in China working on financial deals, and who knows what else (laying the groundwork for ARTguide distribution?) Thomas sure has dropped a lot of hints that endometriosis is a serious problem in China, impacting vast numbers of their female population. He doesn’t strike me as the type to drop trivial information on this message board, wasting his time, and ours, without a reason.
The deals in China haven’t been formally announced by PRED yet, but stick around. Thomas has proven to be a reliable source, and his posts are a treasure trove of important information. (If a person hasn’t figured out Thomas is the real deal by now, investing might not be your calling. Just saying.) Thomas tells us the deals in China took months to solidify, and companies had to thoroughly vet PRED before partnering up, which of course all makes sense.
PRED’s most recent quarterly financials are released, and for a company that is barely getting started, they are fantastic, and once again document significant growth.
Flash forward to Oct 8th when PRED announced they were switching accounting firms to Deloitte, and Thomas confirmed it took many months of reviewing financial documents, past auditing, SEC filings, and making sure there was nothing valid in the hit piece.
I’d say PRED is following through on their promise to grow their business.
Furthermore, they are passing significant hurdles partnering up with major players who never would have signed on with PRED unless their own investigations left no doubt PRED was in fact the real deal.
And let’s not forget their recently announced partnership with Thermo Fisher, formally announced by TMO themselves. You better believe Thermo Fisher took their investigation of PRED as seriously as all of these other companies.
Keep in mind a number of these deals were being solidified, and PRED was going through the process of being thoroughly vetted by multiple well-established worldwide players, while Mr Robinson was being shown the NASDAQ bell he would be ringing at a future date. No wonder he had the biggest grin I’ve ever seen! He didn’t have the look of someone wondering if his house of cards/fake company would be outed through investigations at any moment. He had the look of confidence, and pride, and satisfaction his efforts were soon to be realized. He knew a lot of what was already in full motion behind the scenes, while us investors were clueless. We were all fixated on NASDAQ, when some of the jigsaw pieces had not yet fallen into place.
Is anyone else seeing a pattern here? Because I sure am.
And this is just the information we are aware of so far. What other deals and partnerships are lurking behind the scenes? A person would be incredibly naïve to think PRED has shown us all of their cards at this juncture.
How anyone can post “information” attempting to claim PRED is bogus, is going bankrupt, and their management is dumping shares is beyond me. Worse still, some of you seem to be giving these ideas of impending doom serious contemplation.
There is still a lot of fear with some longs on this board. Look at the facts, not the share price. The share price will follow when it’s time.
There are many intelligent posters here who present valuable fact-based data, filings, and shed light on the rules and regulations of organizations such as the SEC, NASDAQ, etc… There is tremendous value in this.
I’m good at compiling data, noticing patterns, and adding perspective. Most people can’t take emotion out of investing, and look at it objectively, which puts them at a horrific disadvantage. It allows shorts to have success, after spinning their webs of misinformation and deceit.
Use your judgement and intelligence, not your emotional reaction to the pps to decide what is going on with this company, and how you want to proceed.
PRED STRONG!
Almost 550,000 shares traded today.
What do I think?
I think powerful people in the know were buying crazy cheap shares of PRED.
All day long.
The most valuable intel on this board is unquestionably provided in the posts by Thomas HBS. Each and every one of you should go back and read his posts again. We have a direct connection to some of the game plan through Thomas, and I’m guessing that is a rare thing on these boards.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151282922
It’s right in the first paragraph of this post.
Some might complain he predicted an imminent PR after Hong Kong that hasn’t materialized yet. That hardly negates everything he’s posted.
He later explained attorneys on both sides of the deal slow everything down, and it would also fit they might wait to announce when they could couple the news w/other substantial events/PRs.
If people slow down and really read his posts, there is A LOT of information in them.
ASRM conference on reproductive medicine in Philadelphia 10/12-16
9,300 registrants
94 countries represented
220 Exhibitors
PRED has 3 presentations - 2 oral and one poster w/embargoed information that will not be disclosed until the presentations themselves. Material selected through ASRM’s scientific peer-review process.
“The presentations will focus on several features of endometriosis, including genetic mechanisms underlying the disorder, potential disease gene interactions, and the mechanisms through which some benign endometriosis lesions might become cancerous.”
Talk about the perfect venue to shock the world, and launch ARTguide.
Thomas is still laying low.....
Perhaps the fuse has finally been lit.
Maybe, or maybe some feel there are no reliable sources because things have not materialized on their desired timelines.
We all need to base our decisions on the fundamentals we have researched, rather than rumors, or a message board, or whether we have our desired price per share when we want it.
I’m not naive enough to think I’m going to influence how things do or don’t progress.
I’m just passing time here, mostly b/c I too am tired of waiting, and in some odd way, it is cathartic for me.
Why do you think it took as long as it did for me to start posting on this message board? I’ve been invested in PRED over 2 1/2 years. I never thought it would take this long, and I never planned to start participating on a board.
Very intelligent post.
Many have been assuming PRED is itching to be uplifted and it is beyond their control at this point. While I will admit that is a possible scenario, I think it is also entirely possible they just need to pull a few strings whenever they so choose, push the price up, and the uplist happens.
Why is it so impossible to believe PRED is choosing their timing on this uplist? I have heard from multiple reliable sources that NASDAQ loves PRED’s application.
This will be a multibillion dollar company, which means there are some very powerful and wealthy forces coming together in intricate ways beyond our comprehension.
IMHO it’s a big mistake to wait for the NASDAQ uplist to buy shares/more shares.
PRED’s pps will not be at these ridiculously low levels in the relatively near future - and while I have no specific info, I still believe the pps will be significantly higher by Oct 16th. (Yes, it certainly could creep lower in the days to come.)
How do I know PRED is the real deal? Read all of the PRs over the last 2+ years. Read the beyond impressive bios of PRED’s directors/management from the recent 10K. Not a single insider sold a share during the recent run up to near $7. Talk about a perfect time to sell at least some shares if this was a pump and dump! Not one share sold by management. Zero long-term debt. Look at all of the websites of PRED and its subsidiaries. Anybody see PRED’s website 2+ years ago? I did, and it was as sophomoric (although still very intriguing) as they come. Not anymore. Now it’s as good as they come.
I now believe the shorts and hit piece were able to temporarily decrease our stock price low enough to temporarily postpone the uplist to NASDAQ. But as intelligent posters keep mentioning, the NASDAQ application has NOT been denied, b/c that has to be announced. So the application is still alive...waiting for PRED to have enough variables align to punch it through.
Management immediately developed a new game plan, to lift the pps back up to where it needs to be. Again, no guarantees, and it is certainly possible it could take longer, but it sure seems like the next 2 weeks are the perfect opportunity to do that very thing.
When PRED makes its move back up, it will not be subtle. Why do you think there has been the long delay, when the uplist seemed imminent after the application was submitted? Management decided to pick a future time frame that would maximize their chances to have success. I predict we’re about to see a stream of VERY positive news.
There’s blood flowing in the streets, folks, and fear and frustration is everywhere. But the fundamentals, management, and quarterly financials being released are only getting stronger and stronger. I’m no market expert, but I’ve learned enough to know that is the very time to buy, and this could very well be the opportunity of a lifetime. I’ll take my chances on this horse everyday of the week and twice on Sunday, which is why I’m so heavily invested.
I’ve done the math. I’ve done my due diligence. Have you?
PRED STRONG
Could be a big week coming.....
Definitely too early to call, but has Thomas gone quiet? There’s not too many trading days he’s not posting. Quiet yesterday, and so far nothing today.
Calm before the storm?
PRED STRONG
The question isn’t ‘who is selling’, but rather ‘where are the potential buyers’?
The answer is hardly anybody knows about PRED at this time. PRED WANTS to be under the radar. That is, they want to be under the radar until they’re infrastructure is ready, they have the necessary partnerships, financial backing, all parameters of the NASDAQ uplist have been satisfied, etc...
Screaming PRED’s name from the hilltops may not be the wisest move while we are in pinkland.(OTC). As we’ve learned, it can be a very dangerous place to reside.
Ask yourselves how did all of you find PRED? I don’t think I’ve read a single post of someone claiming to have found it on their own (although I’d imagine someone out there might have). We all were given a tip, or had a job interview, or knew someone who knew someone. Myself included.
We don’t have to agree on n PRED’s present game plan of staying under the radar, and we may or may not fully understand the reasoning. But there are an awful lot of incredibly bright minds that have come together in management, and our top notch law firm, and chosen this course of action.
Now imagine when this same group of accomplished minds sets their sites on screaming our name from the rooftops of NASDAQ - when everything is in order. When they’re ready, it will only take a single spark.
Think bigger than wanting instant gratification from a PR representing an event of growth, such as the Hong Kong contract(s). If management released a PR right after the contract was signed, what would happen? We’d all get excited, and sure the pps would rise. But if this wasn’t coupled w/other major events, in a week or two the pps would be right back where it was. How do I know this? B/c I’ve watched and suffered through this exact scenario played out w/PRED numerous times over 2+ years.
The shorts have proven they can have success pushing the price down, even after the incredible bread-trail of outstanding PRs released over the years, which should have PRED’s pps way higher than it is today.
The truth is so long as PRED is OTC, shorts have the upper hand. The difficult part for all of us longs is to fully believe the pps literally does not matter until we are on the NASDAQ. I’ll repeat that because it’s important. PRED’s pps does not matter until we uplist to NASDAQ. (So long as you don’t sell. And I understand that is not easy if you’re bleeding red.)
I guarantee you our management figured this out a long time ago - Again, this is why they keep focusing on growing the business, rather than getting in an un-winnable slugfest with an inexhaustible stream of shorts and even more nefarious characters.
This is also why I believe management has changed their strategy. Develop the business. Ever wonder how many ARTguide tests they are cranking out to ship across the country, to China, and who knows where else? Who knows, maybe PRED actually needs this time to build its infrastructure, be ready w/enough ARTguide tests to fill A LOT or orders.
We need to be thinking big picture here, rather than wondering why we didn’t get a PR x days after we were told about an event. Don’t think, but know rather that this dream team of management w/unquestionable experience is way, way ahead of us.
Get a bunch of PRs to release around the timing of a major event such as the 10/12-16 conference, and launch of Artguide. When these events occur, pps gets jolted big time. and we likely get uplisted easily. And as a nice bonus, investors have a really nice 10k to refer to that was just released.
I mean seriously - wouldn’t you change the corporate strategy considering what we’ve been up against?! I most certainly am not in charge here, but I know I would change the game plan to this kind of strategy if I was. Destroy them w/a sledgehammer of power and facts, and watch them scatter like cockroaches.
Think big picture folks, rather than fixate on that pps, for that is exactly what the shorts are banking on us doing. They can’t argue w/logic, knowledge and due diligence, b/c we’ll beat them every time. They rely on fear and distortion, and they’re very good at it.
PRED STRONG
PRED's management team:
By now, nearly everyone on this board must be familiar with the stellar resumes of PRED's management team.
As long as we're waiting for things to take off, take another look at these individuals running things at PRED. (pulled directly from the 10K released yesterday) Also look at how these same individuals are being compensated with shares of PRED. (also in the 10K) Now factor in how not a single one of these individuals sold a single share, even when the stock price recently went up to just shy of $7. Pump and dump? Not a chance.
There's no other conclusion to come to other than these experienced, seasoned leaders have complete faith in PRED and the direction it is heading. Why else would they leave lucrative, safe, respected positions in well-established companies to come over to upstart PRED? There's no other logical reason, unless they were 100% believers.
BIOGRAPHY
John Sorrentino was elected as Chairman of the Board in October of 2018. Mr. Sorrentino served as Vice President & Chief Operating Officer, Pfizer Vaccine Research & Development, until his retirement in April 2019. At Pfizer, Mr. Sorrentino was responsible for the strategic deployment and management of financial, physical and human resources across nine vaccine research & development sites in seven countries. Mr. Sorrentino manages a broad mix of financial, facility, staffing clinical testing and systems initiatives to support the vaccine portfolio. These efforts span the entire research and development life cycle from early-stage discovery projects through product-registration activities. Mr. Sorrentino was a member of the leadership team that developed and licensed Prevnar 13, the most commercially successful vaccine franchise in history. In his role with Pfizer, Mr. Sorrentino also managed clinical laboratory services and developed staffing, capital, contracting and other assay-strategies required to assess human immune responses to vaccine candidates and to support vaccine label claims. As Pearl River Site Head, Mr. Sorrentino managed a broad spectrum of site operations. He directed external communications, community relations, colleague enrichment/engagement, diversity and other site-related programs. Mr. Sorrentino has more than 35 years of senior management experience in the life-sciences. He has held leadership roles in private and public companies as well as government and non-profit institutions focused on improving the public health. Prior to joining Wyeth/Pfizer in 2003, Mr. Sorrentino held executive management positions in several organizations that provided neonatal screening and related clinical services. In these roles, Mr. Sorrentino pioneered laboratory advances to create efficiency and competitive advantage that led to the expansion of neonatal screening for treatable genetic conditions throughout the world. During his career, Mr. Sorrentino has held final profit and loss responsibility for several organizations and he has been a founder of three companies. He has led mergers and acquisitions and developed successful exit strategies for founders. Mr. Sorrentino has also been a registered lobbyist appearing before state legislators, the US congress and professional societies on a variety of health care and other policy issues. Mr. Sorrentino earned his BA in Chemistry from the University of Massachusetts and MBA from Northeastern University.
The Board of Directors has determined that Mr. Sorrentino’s extensive business and leadership experience in the life sciences industry qualifies him to serve as a member of our Board of Directors.
Mr. Ron Barhorst has been a director since March 2019. Mr. Barhorst worked for ING and ING’s predecessor companies for 25 years. During his tenure he held a broad array of roles. Most recently Mr. Barhorst was the President and CEO of three (3) broker dealers; ING Financial Advisers, LLC, ING Investment Advisors, LLC, and Systematized Benefits Administrators, Inc. He was also the head of ING’s financial advisory business in the US. Mr. Barhorst retired from ING on December 31, 2012. His early career with ING was dedicated to the development of the qualified retirement plan market. Ron’s roles included Regional Manager, District Manager, Regional Vice President and National Head of Health, Education, and Government Sales. Much of his career included appointments to various company boards, and executive level committees. He was also responsible for a large portion of ING’s U.S. based securities registered representative distribution.
-85-
Prior to joining ING, Ron worked as the Head of Residential Services for the Montgomery County (Ohio) Board of Mental Retardation and Developmental Disabilities and was a member of the Governor’s council on deinstitutionalization. Ron created a not-for-profit company, Choices in Community Living, Inc., where he served as the Executive Director. Ron has served on numerous not-for-profit boards including the California Business Roundtable for Education Excellence. He is currently the Chairman of the California State University Board of Governors (system wide foundation) and head of the Executive Committee. Ron has held Chairmanship for the past ten (10) years and has been a member of the board since 2000. Ron is a 1982 graduate of Wright State University and holds a degree in Biology. Ron and his wife, Mitzi, who is also a 1982 graduate of Wright State University, live in Waterford Connecticut.
The Board of Directors has determined that Mr. Barhorst’s extensive business and leadership experience on several board of directors and financial expertise qualifies him to serve as a member of our Board of Directors.
Senator Orrin G. Hatch has been a director since February 2019. Senator Hatch is an attorney and retired politician who served as a U.S. Senator from Utah for 42 years. First elected in 1976, he was the longest-serving Republican U.S. Senator in history. Senator Hatch served as either the chair or ranking minority member of the Senate Judiciary Committee from 1993 to 2005. He previously chaired the Senate Committee on Health, Education, Labor, and Pensions from 1981 to 1987. Senator Hatch also served as Chairman of the Senate Finance Committee. On January 3, 2015, after the 114th United States Congress was sworn in, Hatch became President pro tempore of the Senate. Senator Hatch retired from the U.S. Senate in 2019.
The Board of Directors believes Senator Hatch is qualified to serve on our Board of Directors due to his seven terms as a U.S. Senator, including service as a member or chair of various U.S. Senate committees.
Mr. Jay Moyes has been a director since February 2019. Mr. Moyes previously served as Chief Financial Officer and Director of the publicly traded biomaterials company Amedica Corporation, now SINTX Technologies, where he managed the company's IPO and listing on NASDAQ, and as Chief Financial Officer at publicly traded CareDx, a molecular diagnostics company where he introduced a strategy to reach profitability. Prior to that he held senior finance positions including Chief Financial Officer during his 14-year tenure at publicly traded Myriad Genetics. In addition to overseeing all financial aspects at Myriad as the company transitioned from 10 to more than 900 employees, he was instrumental in raising more than $500 million in public and private financings. He previously was Vice President of Finance and Chief Financial Officer of Genmark, a private genetics company. Mr. Moyes began his career in public accounting at KPMG and serves on the Boards of Directors of Achieve Life Sciences (NASDAQ:ACHV), BioCardia (OTC/QB: BCDA) and Puma Biotechnologies (NYSE:PBYI). In addition to Amedica, he previously was a director and Chairman of the Audit Committee of both Osiris Therapeutics (NASDAQ:OSIR) and Integrated Diagnostics. He also served as a member of the Board of Trustees of the Utah Life Science Association. Mr. Moyes holds a BA in economics from Weber State University and an MBA from the University of Utah.
The Board of Directors believes Mr. Moyes is qualified to serve on our Board of Directors due to his extensive experience in the life sciences industry, his broad leadership experience with Myriad Genetics and on several boards of life science companies, and his experience with financial matters.
-86-
Mr. Bradley Robinson was appointed CEO of Predictive Technology Group, Inc. in March, 2015. Mr. Robinson brings operational, business development and financing experience to Predictive Technology Group, Inc. The majority of this experience was developed during early stage structuring of ventures in the areas of pharmaceuticals, medical device and information technology. He was a founding member of LifeCode Genetics, LLC in 2011 and Predictive Therapeutics, LLC in 2013, both of which are now wholly owned subsidiaries of the Company. Mr. Robinson has been a founding member of other ventures in healthcare, one of which, Specialized Health Products International, Inc., was publicly traded until its acquisition in March of 2008 by C.R. Bard. Mr. Robinson was the CEO and co-founder of Infusive Technologies, LLC from November, 2004 until September, 2008 when it was acquired by Sagent Pharmaceuticals, Inc., a specialty injectable pharmaceutical products company. As part of the acquisition, Mr. Robinson became President of the medical device division of Sagent Pharmaceuticals. He left Sagent Pharmaceuticals in 2010 to become Vice President of Business Development of Juneau BioSciences, which develops and commercializes genetic tests related to women’s healthcare. He was responsible for developing strategic partnerships and the company’s capitalization. Mr. Robinson studied accounting at the University of Utah and earned an MBA/MIM from the Graduate School of International Management (Thunderbird).
The Board of Directors believes Mr. Robinson’s extensive leadership, executive, managerial, business and healthcare industry experience qualifies him to serve as a member of our Board of Directors. In addition, Mr. Robinson’s day-to-day management and intimate knowledge of our business and operations provide our Board with an in-depth understanding of the Company.
Mr. Michael Dey, Ph.D., was elected as a member of the Board of the Company and CEO of Predictive Therapeutics, a wholly-owned subsidiary of the Company, in June of 2016. Prior to joining Predictive Therapeutics, Dr. Dey was an executive at Wyeth where he was the President of Scientific Affairs for Wyeth’s Women’s Health Care business. Prior, Dr. Dey was the President of Wyeth Women’s Health Care which he managed for 7 years. Dr. Dey had worldwide responsibility for this consolidated unit of more than $3 billion annually that included all of Wyeth’s Women’s Health Care resources globally. Prior to his leadership role in women's health care he served as Vice President, General Manager of ESI Pharma, Inc. In 1995, with Wyeth’s acquisition of American Cyanamid and Lederle Standard Products, Dr. Dey became President of ESI Lederle, Inc. As President of ESI Lederle, his responsibilities included directing one of the largest generic drug companies in the U.S. with more than $500 million in sales, approximately 150 employees in R&D and 100 employees in Marketing and Sales. ESI Lederle sold both oral and injectable products that included Tubex®, the prefilled syringe delivery system. Dr. Dey received a BS in Biology/Chemistry from Western Washington University, an MS degree in Pharmacology-Toxicology from the University of California, Davis, and a PhD in Pharmacology-Toxicology from Washington State University.
The Board of Directors believes that Dr. Dey is qualified to serve on our Board of Directors due to his extensive experience within the field of drug discovery and development, his broad leadership experience on various boards, and his financial expertise with life sciences companies.
Mr. Simon Brewer, CPA, was appointed to the Company’s Chief Accounting Officer in January of 2018, and Chief Financial Officer in July of 2018. Prior to joining our Company, Mr. Brewer served as Chief Financial Officer of Norbest, LLC from 2016 to 2017, where he was responsible for Norbest’s finance, accounting, HR and IT functions. Prior to joining Norbest, Mr. Brewer was Vice President, Finance and IT for Wilson Electronics, LLC from 2013 to 2016. Reporting directly to the CEO of Wilson Electronics, Mr. Brewer oversaw significant growth for the electronics company operating in all 50 states and internationally in several countries. Mr. Brewer assisted heavily in building scalable processes, modernizing the business, international growth in Asia, and an acquisition of a main competitor. Before that, he was Senior Director and Corporate Controller for Backcountry.com, Inc. from 2009 to 2013. Mr. Brewer implemented Sarbanes Oxley when Backcountry.com was purchased by a publicly traded Company, Liberty Interactive, as well as started the FP&A function for modernizing data driven decision making. Mr. Brewer started his accounting career as a CPA for KPMG LLP from 2005 to 2009, working on audits, IPOs, bankruptcies, divestitures, and acquisitions. Mr. Brewer received his BA and Masters of Accounting degrees, along with a minor in Russian, from The University of Utah. Mr. Brewer is a CPA licensed in Utah and Nevada.
-87-
Mr. Paul Evans was appointed Chief Operating Officer in June of 2018. Prior to joining the Company, Mr. Evans was Vice President of Intellectual Property at Vivint, Inc. from 2014 to 2015, where he led the development, management, and enforcement of Vivint’s intellectual property portfolio across the company’s entire platform of smart home solutions, including security and surveillance, smart home control, wireless internet, and cloud storage. From 2010 to 2013, Mr. Evans was General Counsel, Executive VP of Corporate Development, and Chief Governance and Compliance Officer at InTouch Health, a leading provider of telehealth enterprise network and managed services to hospitals and healthcare systems for the delivery of specialty clinical care to patients. Prior to joining InTouch Health, Mr. Evans was an attorney with Stoel Rives LLC from 2008 to 2010. From 2000 to 2008, he was General Counsel, VP of Business Development, Chief Governance and Compliance Officer of Specialized Health Products International, Inc., a medical device company acquired by C.R. Bard in 2008. Mr. Evans earned his BS in Mechanical Engineering, JD, and MBA degrees from The University of Utah.
Mr. Eric Olson is Executive Vice President, and the founder and Chief Executive Officer of Predictive Biotech, Inc., since he joined the Company in 2016. His previous experience includes over 25 years developing and commercializing innovative technologies in devices, diagnostics, biologics and biomaterials. The last 8 years of his career, Mr. Olson has served in the role of either President, Chief Executive Officer or Board Member. Prior to joining Predictive Technology Group, Mr. Olson was the President and CEO for Cupertino, CA based Skeletal Kinetics. This Colson & Associates company developed and commercialized synthetic bone substitute products for Orthopedic and Spinal applications. Previous to that, Mr. Olson was the President, CEO and Board Member for Amedica Corporation. Amedica manufactured and distributed cortical and cancellous silicon nitride ceramic interbody devices for spine. In addition, the company distributed a line of HCT/Ps designed to work in conjunction with the ceramic biomaterial. Mr. Olson took Amedica Corporation public in 2014. Mr. Olson began his career with Smith & Nephew and has worked with Johnson & Johnson, Medtronic and Wright Medical in Sales and Marketing leadership roles. Mr. Olson earned his BS in Behavioral Science and Health Administration degrees from The University of Utah.
Mr. Michael Herbert was appointed Chief Marketing Officer in February of 2017. Prior to joining our Company, Mr. Herbert was Chief Marketing Officer at Flagship Health Group 2011 to 2017, where he worked with many of the top insurers on their go-to-market strategies. Mr. Herbert’s focus has been on strategic brand building, channel alignment, product development and positioning across a broad spectrum of health care and consumer companies. He has held senior leadership and ownership positions in early through mid stage companies, including Bianchi (SVP Sales and marketing 1984 – 1996), Castelli (CEO, 1996 – 2004), Shock Doctor (Chief Sales and Marketing Officer 2004 – 2009), and DreamGuard (Chief Sales and Marketing Officer 2009 – 2011), leading to multiple successful transactions.
I still believe everything is going to happen more or less all at once - a couple of major PRs (including at least one Hong Kong deal), the Oct 12-16 ASRM conference, (where PRED is going to educate the world), the Artguide launch, and the NASDAQ uplist.
The financials release yesterday were fantastic for a company that has yet to kick things into gear.
PRED is done messing around with any shorts, and potential hit pieces.
When PRED makes its move, it will be swift, brutal, and undeniable, and all of you who have been complaining will be quick to forgive being kept in the dark. Don't mistake the quiet for a lack of an efficacious business model.
When we are uplisted to NASDAQ, and PRED opens the floodgates with PRs, I think most of us (myself included) will literally be speechless. I've been told (again I will keep my source to myself) there are no less than 20 major PRs all set to go when this gets started. Let that sink in. 20.
My contact has been right across the board with what he said would come with PRED. Sometimes it took a little more time to get there than initially thought, but PRED has gotten there....every.....single....time.
Are you longs ready?! It's coming....
No guidance on timing of uplist.
In fact, similar to others posting here, my sources have gone dead quiet. I look at that as a good thing. Calm before the storm. The yacht is about to be launched, and nobody wants to potentially rock the boat when we are this close.
It doesn’t count for anything, but my personal opinion now, is that we will get a great earnings report Monday, significant press releases will start to be released, the October conference will be a smash hit, and Artguide will in fact be launched during that conference, and then we will easily get the NASDAQ uplist - quickly followed by a significant number of heavy hitting press releases.
I’ve posted it before. Mark October 16 on your calendar. Us long should be very happy campers by that date, if not before. Shorts...not so much.
I honestly think that is a very intelligent theory, and I’m a little embarrassed I hadn’t considered it yet.
While I had not mentioned it yet, I too have sources high up. No I will not burn them, but they have not been concerned in the slightest, and went so far as to say the hit job wasn’t going to impact anything, oher than a paper loss temporarily, as well as instigating fear, that would ultimately be short term.
I admit I was concerned with their lack of concern! But if this theory holds water, and it very well may, that would explain things.
PRED $25 - $30 pps by year end 2019?
Still a realistic possibility, or might it take a little longer to get there?
It sure seems like a possibility to me if Monday’s ER, upcoming PRs, ASRM Oct conference, and ARTguide launch play out the way they could.
Still holding to that prediction, Thomas?
If it’s really true the ARTguide test is being launched during the ASRM conference Oct 12-16, that is enormous.
Between that, the presentations on endometriosis, PRs (plural) on Hong Kong partnerships, and quarterly financials, which should be out by the end of September, I’m putting October 16 on my calendar.
If big things haven’t happened by October 16, to turn this around, then I will be worried.
For the record, I expect big things by then. I figure, we can all wait 23 more days.
https://events.jspargo.com/ASRM19/Public/eBooth.aspx?IndexInList=173&FromPage=Exhibitors.aspx&ParentBoothID=&ListByBooth=true&BoothID=640847
Perhaps I missed it somewhere along the way, but this is the first time I remember reading, in addition to infertility, and women’s health, and rumors of cancer, CTE, and CAD, PRED will also be focusing on “childhood diseases”.
I find that very interesting.
This keeps getting bigger and bigger.
Probably should have kept reading Hatch’s Wikipedia page on social issues:
In 2013, Hatch, “endorsed same-sex couples' right to form a civil union, stating that the law should ‘give gay people the same rights as married people’.[96] Later that same year, Hatch voted in favor of the Employment Non-Discrimination Act, legislation creating protected classes for those identifying as gay, lesbian, bisexual or transgender.[97][98] In 2018, Hatch ‘honored Pride’ by giving a speech in support of programs to help and serve LGBT youth.”
(It’s always important to look at all information on a timeline, not just cherry pick information that serves one’s objectives.)
Good God I’m tired of the ludicrous short posts, w/out any real thought, intelligent argument, and due diligence.
It must mean PRED is about to take off. I have over 365,000 shares, and I’m not selling a single one until the PPS is over $35.
Not.....one....
100% correct Bigboy.
Like it or not, we're all in the dark regarding why PRED management is not releasing more information at this juncture to appease us investors. Believe me, I don't like it either. I own a ton of shares. I probably bought more than I should have, but I'm a believer.
We need to keep reminding ourselves of the pedigree our management holds across the board with all positions, and who they have hired to represent them legally, with accounting, etc... I've never seen anything like it with other companies.
There has to be a game plan, and my guess is it's a great game plan. We just can't see the whole picture, because we don't have all the necessary information to make a fully educated deduction. Those of us who have been waiting for years are beyond frustrated, and understandably so.
While I don't know, I'm guessing everything hinges on the NASDAQ uplist. I would imagine there's a variable or two that has yet to be fulfilled that is preventing the uplist. What are those variable? I honestly don't know. But when those variables falls into place via the natural progression of the company developing, forming partnerships, attaining necessary financial backing, etc, the uplist will happen, and then the rocket ship will be launched - and my guess is it will be a site to behold!
And remember, that's exactly what PRED told everyone recently. Rather than engage in defending themselves against an attack, they preferred to continue developing their company - presumably to satisfy all requirements for the uplist, which is ultimately what we longs are waiting for.
I do know PRED has not been rejected by NASDAQ, because that announcement would have to made within 3 days of that event occurring. We've seen no such rejection. Therefore the application must still be alive.
We can't see the whole picture right now. I'm as frustrated as everyone else.
Therefore, there's only one logical conclusion for those of us who believe we've found a diamond in the rough....more patience....let PRED management attain those last variables. You know they want it as badly as we do. Probably more. After all, they're the ones who put in all the work.
PRED STRONG!
Hey Thomas,
I just wanted to join the list of people thanking you for actually taking the time to keep us long shareholders of PRED informed.
I've been a significant investor in PRED for over 2 years now, and the number of shares I hold is substantial.
I'm not going to lie. The wait for this company's rocket ship to 'take off' has been painful at times, and that's probably an understatement.
I have yet to sell a single share. The more I see shorts post, the more determined I become to keep....every....single.....share.....regardless of the wait.
We understand your hands are tied with how much information you can pass on to us longs, but whatever you can share to help us keep the faith during the wait sure would be appreciated.
Thanks again.